Mark Hopman, Chief Commercial Officer at Beta Bionics, Inc. (BBNX), sold 36,458 shares at $20.56 ($742K) on 2025-09-05, disclosed to the SEC on 2025-09-08.
Scheduled sale ($742k) by Chief Commercial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $19.97 | 6,818 | $136K | 18.4% |
| 2 | $19.97 | 6,818 | $136K | 18.4% |
| 3 | $20.56 | 11,411 | $235K | 31.6% |
| 4 | $20.56 | 11,411 | $235K | 31.6% |
| Total | $20.34 avg | 36,458 | $742K | 100% |
| Filing → |
| BBNX | SELL | 2026-09-17 | $620K | — | Filing → |
| BBNX | SELL | 2026-09-15 | $12K | — | Filing → |
| BBNX | SELL | 2026-09-10 | $681K | — | Filing → |